A HER2/3 targeting dendritic cell vaccine, alpha-DC1, has been subjected to a phase II trial (NCT04348747) on TNBC and HER2 + breast cancer patients who have brain metastases [212]. Here, ERBB2 is linked to breast carcinoma.